Thought this was JL's best call yet. very bullish
Post# of 148181
Sounds like the P2 enrollment improved by about 15-18 more. I'd rather see them finish the trial and collect all data. Last thing I'd want to see is the FDA come back to them for more data. It's a 2 week trial and not worth the risk.
I think it's a hard decision to cease the eIND access but I understand the decision. Hopefully, some patients are within a reasonable drive to clinical trial centers.
Kind of funny that NP mentioned the non-binding LOI considering his last comment about NBLOI's was that they weren't worth mentioning until they were binding. But i'll take it.
Looks like uplisting and the Mexico trial are moving along quickly.